Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.

Literature DB >> 15135713

Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.

John T Parissis¹, Stamatis Adamopoulos, Charalambos Antoniades, George Kostakis, Antonios Rigas, Stamos Kyrzopoulos, Efstathios Iliodromitis, Dimitrios Kremastinos.

Abstract

This randomized, placebo-controlled trial showed that levosimendan administration causes a significant reduction of circulating proinflammatory cytokine interleukin-6 and soluble apoptosis mediators, such as soluble Fas and Fas ligand in patients with decompensated heart failure. These immunomodulatory effects may lead to improvement of symptoms and echocardiographic markers of cardiac contractile performance in these patients.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2004 PMID： 15135713 DOI： 10.1016/j.amjcard.2004.01.073

Source DB: PubMed Journal: Am J Cardiol ISSN： 0002-9149 Impact factor: 2.778

Keyword Cloud
Cited

36 in total

1. Effects of combined levosimendan and vasopressin on pulmonary function in porcine septic shock.

Authors: Muhuo Ji; Renqi Li; Guo-min Li; Yunxia Fan; Lin Dong; Jianjun Yang; Yong G Peng; Jing Wu
Journal: Inflammation Date: 2012-06 Impact factor: 4.092

2. Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial.

Authors: David B Antcliffe; Shalini Santhakumaran; Robert M L Orme; Josie K Ward; Farah Al-Beidh; Kieran O'Dea; Gavin D Perkins; Mervyn Singer; Daniel F McAuley; Alexina J Mason; Mary Cross; Deborah Ashby; Anthony C Gordon
Journal: Intensive Care Med Date: 2019-08-19 Impact factor: 17.440

Review 3. A global perspective on vasoactive agents in shock.

Authors: Djillali Annane; Lamia Ouanes-Besbes; Daniel de Backer; Bin DU; Anthony C Gordon; Glenn Hernández; Keith M Olsen; Tiffany M Osborn; Sandra Peake; James A Russell; Sergio Zanotti Cavazzoni
Journal: Intensive Care Med Date: 2018-06-04 Impact factor: 17.440

4. Levosimendan reduces plasma cell-free DNA levels in patients with ischemic cardiomyopathy.

Authors: Apostolos Zaravinos; Spiros Tzoras; Stavros Apostolakis; Kyriakos Lazaridis; Demetrios A Spandidos
Journal: J Thromb Thrombolysis Date: 2011-02 Impact factor: 2.300

5. Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery.

Authors: K Distelmaier; C Roth; L Schrutka; C Binder; B Steinlechner; G Heinz; I M Lang; G Maurer; H Koinig; A Niessner; M Hülsmann; W Speidl; G Goliasch
Journal: Br J Anaesth Date: 2016-07 Impact factor: 9.166

6. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass.

Authors: Ricardo Levin; Marcela Degrange; Carlos Del Mazo; Eduardo Tanus; Rafael Porcile
Journal: Exp Clin Cardiol Date: 2012-09

Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.

1. Effects of combined levosimendan and vasopressin on pulmonary function in porcine septic shock.

2. Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial.

Review 3. A global perspective on vasoactive agents in shock.

4. Levosimendan reduces plasma cell-free DNA levels in patients with ischemic cardiomyopathy.

5. Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery.

6. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass.

Review 7. [Role of Levosimendan in intensive care treatment of myocardial insufficiency].

8. [Pilot study of levosimendan : Effect on liver blood flow and liver function in acute decompensated heart failure].

Review 9. Clinical pharmacology of levosimendan.

10. Levosimendan: from basic science to clinical practice.